Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Karsten Munk Knudsen, CFO of Novo Nordisk, discusses the prospect of tariffs on pharmaceuticals and the importance of the U.S ...

Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, after a major profit ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from ...

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

Shares of Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, fell in pre-market trading and on the ...

Super Micro, AMD, and Snap stocks tumbled after quarterly earnings reports. Arista and Disney stocks were rising.

The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for drugmakers to immediately lower their prices for Medicaid. This comes as Novo ...